Single User
£3750
PDF
44 pages

Muscular Dystrophies Forecast in 12 Major Markets 2017-2027


The muscular dystrophies (MD) are a group of more than 30 genetic diseases characterized by progressive muscle weakness and degeneration leading to reduced mobility. The specific types of MD are classified based on severity, pattern of inheritance, age at onset, affected muscle groups or other organs, specific genetic mutation and gender affected.  Different forms of MD can manifest at different stages of life, from infancy to late adulthood. The different types of MD can affect different organs and systems such as the brain, heart, blood vessels, muscles of respiration and gastrointestinal tract.

This report provides the current prevalent population for Muscular Dystrophies across 12 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Brazil, Japan, India, China and Russia) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Muscular Dystrophies have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Co morbidities associated with MD include:

  • Motility impairment
  • Contractures
  • Respiratory failure
  • Cardiomyopathy
  • Cognitive impairment
  • Visual loss
  • Hearing impairment

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy
  • Able to quantify patient populations in global Muscular Dystrophies market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of Muscular Dystrophies and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on Muscular Dystrophies prevalent
  • Identify sub-populations within Muscular Dystrophies which require treatment.
  • Gain an understanding of the specific markets that have the largest number of Muscular Dystrophies patients.
Table of Contents
  • List of Tables and Figures
  • Introduction
  • Cause of the Disease
  • Risk Factors & Prevention
  • Diagnosis of the Disease
  • Variation by Geography/Ethnicity
  • Disease Prognosis & Clinical Course
  • Key comorbid conditions/Features associated with the disease
  • Methodology for quantification of patient numbers
  • Top-line prevalence for Muscular Dystrophies
  • Type of Muscular Dystrophies
  • Abbreviations used in the report
  • Other Black Swan Analysis Publications
  • Black Swan Analysis Online Patient-Based Databases
  • Patient-Based Offering
  • Online Pricing Data and Platforms
  • References
  • Appendix
List of Tables
  • Features of different subtypes of MDs
  • Genes associated with different types of MD
  • Prevalence of Muscular Dystrophies, total (000s)
  • Prevalence of Muscular Dystrophies, males (000s)
  • Prevalence of Muscular Dystrophies, females (000s)
  • Prevalence of different types of MD, total (000s)
  • Abbreviations and Acronyms used in the report
  • USA prevalence of Muscular Dystrophies by 5-yr age cohort, males (000s)
  • USA prevalence of Muscular Dystrophies by 5-yr age cohort, females (000s)
  • Canada prevalence of Muscular Dystrophies by 5-yr age cohort, males (000s)
  • Canada prevalence of Muscular Dystrophies by 5-yr age cohort, females (000s)
  • France prevalence of Muscular Dystrophies by 5-yr age cohort, males (000s)
  • France prevalence of Muscular Dystrophies by 5-yr age cohort, females (000s)
  • Germany prevalence of Muscular Dystrophies by 5-yr age cohort, males (000s)
  • Germany prevalence of Muscular Dystrophies by 5-yr age cohort, females (000s)
  • Italy prevalence of Muscular Dystrophies by 5-yr age cohort, males (000s)
  • Italy prevalence of Muscular Dystrophies by 5-yr age cohort, females (000s)
  • Spain prevalence of Muscular Dystrophies by 5-yr age cohort, males (000s)
  • Spain prevalence of Muscular Dystrophies by 5-yr age cohort, females (000s)
  • UK prevalence of Muscular Dystrophies by 5-yr age cohort, males (000s)
  • UK prevalence of Muscular Dystrophies by 5-yr age cohort, females (000s)
  • Brazil prevalence of Muscular Dystrophies by 5-yr age cohort, males (000s)
  • Brazil prevalence of Muscular Dystrophies by 5-yr age cohort, females (000s)
  • Japan prevalence of Muscular Dystrophies by 5-yr age cohort, males (000s)
  • Japan prevalence of Muscular Dystrophies by 5-yr age cohort, females (000s)
  • India prevalence of Muscular Dystrophies by 5-yr age cohort, males (000s)
  • India prevalence of Muscular Dystrophies by 5-yr age cohort, females (000s)
  • China prevalence of Muscular Dystrophies by 5-yr age cohort, males (000s)
  • China prevalence of Muscular Dystrophies by 5-yr age cohort, females (000s)
  • Russia prevalence of Muscular Dystrophies by 5-yr age cohort, males (000s)
  • Russia prevalence of Muscular Dystrophies by 5-yr age cohort, females (000s)
Brazil, Canada, China, France, Germany, India, Italy, Japan, Russian Federation, Spain, United Kingdom, United States of America